ArgoMed Seeks Partner To Distribute Low-Cost BPH Treatment Device
This article was originally published in The Gray Sheet
Executive Summary
ArgoMed is planning to put its Thermoflex system for treatment of benign prostatic hyperplasia in the hands of a distribution partner capable of clearing a path into an already crowded market.
You may also be interested in...
ArgoMed
Convertible line of credit supplied via strategic alliance with Quintiles Transnational will be used to establish a sales force for a full-scale U.S. launch of ArgoMed's Thermoflex system for benign prostatic hyperplasia, ArgoMed announces May 2. The heated water therapy system gained 510(k) clearance in August 1999, but a full-scale launch was delayed pending suitable distribution arrangements (1"The Gray Sheet" Oct. 11, 1999, p. 20). A separate agreement with Timm Medical Technologies, announced May 3, will provide exclusive North American distribution rights for direct marketing to urologists offices
ArgoMed
Convertible line of credit supplied via strategic alliance with Quintiles Transnational will be used to establish a sales force for a full-scale U.S. launch of ArgoMed's Thermoflex system for benign prostatic hyperplasia, ArgoMed announces May 2. The heated water therapy system gained 510(k) clearance in August 1999, but a full-scale launch was delayed pending suitable distribution arrangements (1"The Gray Sheet" Oct. 11, 1999, p. 20). A separate agreement with Timm Medical Technologies, announced May 3, will provide exclusive North American distribution rights for direct marketing to urologists offices
BPH Treatment Devices To Be Reimbursed By HCFA At Approximately $1,875
EDAP expects that the lower cost of its Prostatron microwave-based system for treating benign prostatic hyperplasia will make the product more attractive than competing devices now that therapy has been assigned an ambulatory payment classification (APC) code with a set reimbursement level.